Abstract:
Monoclonal antibodies are used to block control points of the tumor development of
many oncological pathologies. One of the critical control points of tumor development of several
oncological pathologies is the receptor for cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
Monoclonal antibodies against the CTLA-4 receptor are laboratory-derived humanized antibodies.
An essential step in the humanization of antibodies is the production of murine hybrid cells
producing monoclonal antibodies. This article describes studies of mice monoclonal antibodies
against a recombinant human CTLA-4 receptor (rCTLA-4) expressed in Escherichia coli. To obtain
strains of hybrid cells producing monoclonal antibodies were used methods of hybridoma
technology. As a result, hybrid cells producing monoclonal antibodies to CTLA-4 were obtained.
Strains of hybrid cells have high productive activity in vitro and in vivo. Monoclonal antibodies
react with rCTLA-4 protein, belong to the class of IgG1, and have a high binding constant. They
efficiently bind to the rCTLA-4 receptor and block the interaction of rCTLA-4 with the commercial
recombinant human B7-1 Fc and rhesus monkey PD-1 hFc proteins. These monoclonal antibodies
to rCTLA-4 can be used to obtain recombinant humanized monoclonal antibodies to the human
CTLA-4 receptor.
